Abstract
West J Emerg Med. 2016 May;17(3):264–70.
Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016.
Christos S, Naples R.
Erratum in
West J Emerg Med. 2016 September;17(5):669–70. Dosage error in published figure; MEDLINE/PubMed Figure 3 is corrected and provided.
PMCID: PMC4899056 [PubMed - indexed for MEDLINE]
In the Review Article entitled “Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016,” published in the May 2016 issue of the Western Journal of Emergency Medicine (2016;17(3):264–70. DOI: 10.5811/westjem.2016.3.29294), there were the following errors in the published article.
Figure 3.
Reversal of direct oral anticoagulants (DOACs) in patients with significant bleeding.
IV, intravenous; FFP, fresh frozen plasma; rFVIIa, Recombinant human Factor VIIa; PCC, prothrombin complex concentrates; FEIBA, Factor Eight Inhibitor Bypassing Activity; NG, nasogastric
#Off label use.
^4F-PCC contains heparin and is contraindicated in patients with a history of heparin induced thrombocytopenia.
¥Not currently available on market. FDA trials ongoing. Dosing based on published Phase 3 trial.
Footnotes
Full text available through open access at http://escholarship.org/uc/uciem_westjem